MAY 14, 2018 10:18 PM PDT

Gilenya: First Treatment for Pediatric MS

WRITTEN BY: Nouran Amin

 

 A drug known as Gilenya (fingolimod), which was first approved in 2010 for the treatment of Multiple Sclerosis (MS) in adult patients, was recently re-approved by the U.S. Food and Drug Administration as the first official treatment option for relapsing form of multiple sclerosis (MS) in children and adolescents age 10 years and older.

“For the first time, we have an FDA-approved treatment specifically for children and adolescents with multiple sclerosis,” explains Billy Dunn, M.D., director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “Multiple sclerosis can have a profound impact on a child’s life. This approval represents an important and needed advance in the care of pediatric patients with multiple sclerosis.”

MS is an autoimmune disease of the central nervous system (CNS) caused by a disruption between the brain and other parts of the body. MS is characterized by chronic and inflammatory phenotypes. It is the most common neurological disability in young adults, occurring more frequently in women than men. For many individuals with MS, periods of worsening function and appearance of new symptoms, known as relapses or flare-ups, begin by recovery periods or remissions. Over time, recovery may not be completely fulfilled, this leads to the progressive stage of MS consisting of a decrease in function and an increase in disability. Furthermore, many with MS will experience their first symptoms, such as vision problems or muscle weakness, between the ages of 20 to 40 and about two to five percent will have symptoms onset before age 18. The estimates suggest that 8,000 to 10,000 pediatric-aged individuals in the U.S. have MS.

The effectiveness of Gilenya in treating pediatric patients was evaluated by comparison to another MS drug (interferon beta-1a) in a clinical trial involving 214 patients between the ages of 10 to 17. The results showed that 86% of patients receiving Gilenya were MS relapse-free after two years of treatment in comparison to 46% of those patients administered the interferon beta-1a.

In pediatric patients, Gilenya possessed side effects which were quite similar to those exhibited in adults. The most common symptoms included headache, liver enzyme elevation, diarrhea, cough, flu, sinusitis, back pain, abdominal pain and pain in extremities.

The administration of Gilenya consists of dispensation with a patient Medication Guide that details crucial information about the use and risk of the drug. The serious risks include a slow heart especially after the first dose of Gilenya. Additionally, Gilenya may increase the risk of infection particularly a form of brain infection known as progressive multifocal leukoencephalopathy (PML). It can also cause harm to the developing fetus, lead to vison complications, and serious respiratory problems.

The FDA granted Priority Review and Breakthrough Therapy designation for this indication.

 

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
APR 11, 2020
Drug Discovery & Development
APR 11, 2020
Remdesivir Improves COVID-19 Symptoms in 68% of Patients in Early Study
An early analysis of remdesivir, a drug developed by pharmaceutical firm Gilead, has shown that it may have improved sev ...
APR 13, 2020
Cardiology
APR 13, 2020
Computer Model Predicts How Drugs Affect Heart Rhythm
Cardiotoxicity, heart electrophysiology dysfunction or muscle damage,  is one of the most common reasons why drugs ...
APR 17, 2020
Cannabis Sciences
APR 17, 2020
Does CBD Really Ease Arthritis Pain?
Cannabis products are increasingly used to treat chronic pain from arthritis. As its non psychoactive ingredient, cannab ...
MAY 08, 2020
Drug Discovery & Development
MAY 08, 2020
Cholesterol Drugs May Boost Healthy Gut Bacteria in Obese People
While statins have long been known for their efficacy in treating high cholesterol, until recently, there was no evidenc ...
MAY 17, 2020
Cell & Molecular Biology
MAY 17, 2020
Potential Treatment for Brain and Spinal Cord Injury is IDed
Treatment options are limited for people that have suffered swelling-inducing injuries to their brain and spinal cord. N ...
MAY 29, 2020
Genetics & Genomics
MAY 29, 2020
Advances in Our Understanding of Huntington's Disease
Huntington's disease (HD) is a fatal neurodegenerative disease caused by an expanded sequence in the huntingtin gene.
Loading Comments...